Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.44 |
| ▸ | TSHR | P16473 | 6/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15708402 | 0.88 | TRPM2 (0.48) | LMNATSHRGAANPSR1TDP1 | |
| SCHEMBL18853768 | 0.79 | LMNA (0.37) | LMNATSHRGAANPSR1TDP1 | |
| SCHEMBL14484662 | 0.77 | TRPM2 (0.48) | LMNATSHRGAANPSR1TDP1 | |
| SCHEMBL15724296 | 0.76 | LMNA (0.49) | LMNATSHRGAANPSR1TDP1 | |
| SCHEMBL15730094 | 0.75 | LMNA (0.33) | LMNATSHRGAANPSR1TDP1 | |
| SCHEMBL15724337 | 0.75 | SMN1; SMN2 (0.47) | LMNATSHRGAANPSR1TDP1 | |
| SCHEMBL14555660 | 0.73 | TRPM2 (0.46) | LMNATSHRGAANPSR1TDP1 | |
| SCHEMBL17067046 | 0.73 | LMNA (0.61) | LMNATSHRGAANPSR1TDP1 | |
| SCHEMBL14555876 | 0.72 | TRPM2 (0.46) | LMNATSHRGAANPSR1TDP1 | |
| SCHEMBL18328262 | 0.70 | LMNA (0.44) | LMNATSHRGAANPSR1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140142085-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. (US) | 2014-05-22 | — | — | US | disclosed |
| US-20140142085-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. (US) | 2014-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140142085-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | CCR5, NPC1, FURIN | LMNA 3182/4885TSHR 4824/4885GAA 148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.